📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Oculogica

1.1 - Company Overview

Oculogica Logo

Oculogica

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of neuro-diagnostic medical devices and training focused on TBI, concussion, and eye-tracking. Products include EyeBOX, an FDA-cleared, baseline-free, non-invasive device that tracks eye movements to aid in concussion (mTBI) diagnosis with results in under four minutes, and OcuPro, a roadside test for law enforcement to detect recent cannabis use and impairment. Offers EyeBOX training to customers.

Products and services

  • EyeBOX: FDA-cleared, baseline-free, non-invasive device that tracks eye movements and generates a BOX score in under 4 minutes to indicate likelihood of concussion (mTBI) for clinical neuro-diagnostics
  • OcuPro: Roadside test developed for law enforcement that delivers immediate results to detect recent cannabis use and impairment
  • EyeBOX Training: Customer-only training on EyeBOX device use and interpretation of BOX score results for concussion assessment, available exclusively to current customers

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Oculogica

Anelixis Therapeutics Logo

Anelixis Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage drug development focused on immune modulatory therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD); facilitates pre-clinical drug development. Based in Cambridge, Massachusetts.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Anelixis Therapeutics company profile →
Concert Pharmaceuticals Logo

Concert Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage biotechnology developing drug products via a novel precision deuterium chemistry platform, modifying specific properties of validated drug molecules to create new medicines that address patient needs, yielding a rich pipeline.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Concert Pharmaceuticals company profile →
Embera NeuroTherapeutics Logo

Embera NeuroTherapeutics

HQ: United States Website
  • Description: Provider of development-stage pharmaceutical therapies for smoking cessation and other addictions with limited or no approved treatments. Developing EMB-001, a patented combination of metyrapone and oxazepam targeting complementary brain pathways and moderating activity in the stress response system. Completed Phase 1 studies in smokers; Phase 2 ongoing in cocaine use disorder and smoking cessation.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Embera NeuroTherapeutics company profile →
Transition Therapeutics Logo

Transition Therapeutics

HQ: Canada Website
  • Description: Provider of biopharmaceutical therapeutics targeting disease indications with large markets. Lead products include ELND005 for the treatment of Alzheimer’s disease and TT223 for the treatment of diabetes, with an emerging pipeline of preclinical drug candidates acquired externally.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Transition Therapeutics company profile →
Envoy Therapeutics Logo

Envoy Therapeutics

HQ: United States Website
  • Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Envoy Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Oculogica

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Oculogica

2.2 - Growth funds investing in similar companies to Oculogica

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Oculogica

4.2 - Public trading comparable groups for Oculogica

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Oculogica

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Oculogica

What does Oculogica do?

Oculogica is a provider of neuro-diagnostic medical devices and training focused on TBI, concussion, and eye-tracking. Products include EyeBOX, an FDA-cleared, baseline-free, non-invasive device that tracks eye movements to aid in concussion (mTBI) diagnosis with results in under four minutes, and OcuPro, a roadside test for law enforcement to detect recent cannabis use and impairment. Offers EyeBOX training to customers.

Who are Oculogica's competitors?

Oculogica's competitors and similar companies include Anelixis Therapeutics, Concert Pharmaceuticals, Embera NeuroTherapeutics, Transition Therapeutics, and Envoy Therapeutics.

Where is Oculogica headquartered?

Oculogica is headquartered in United States.

How many employees does Oculogica have?

Oculogica has 1,000 employees 🔒.

When was Oculogica founded?

Oculogica was founded in 2010 🔒.

What sector and industry vertical is Oculogica in?

Oculogica is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Oculogica

Who are the top strategic acquirers in Oculogica's sector and industry

Top strategic M&A buyers and acquirers in Oculogica's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Oculogica?

Top strategic M&A buyers groups and sectors for Oculogica include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Oculogica's sector and industry vertical

Which are the top PE firms investing in Oculogica's sector and industry vertical?

Top PE firms investing in Oculogica's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Oculogica's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Oculogica's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Oculogica's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Oculogica include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Oculogica's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Oculogica?

The key public trading comparables and valuation benchmarks for Oculogica include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Oculogica for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Oculogica with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Oculogica's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Oculogica with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Oculogica's' sector and industry vertical?

Access recent funding rounds and capital raises in Oculogica's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Oculogica